March 18, 2019. We support FDA’s efforts to update their approach to address growing concerns about cybersecurity risks in medical devices through the premarket submission process. Software and medical devices have become increasingly interconnected and vulnerable to network-related cybersecurity breaches, which puts patients at risk. We have several concerns and recommendations to improve the updated guidance.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
Here are our Statements and Positions on issues that affect you.
NCHR Testimony on the Evaluation for High-Risk HPV Detection Devices
NCHR testified on March 8th, 2019 at the Microbiology Advisory Committee urging panel members to consider increasing the screening age from 25 to 30.
Read More »NCHR Statement to the Maryland State House Environmental Committee, Artificial Turf
NCHR’s Jack Mitchell made a statement at the Maryland State House Environmental Committee regarding artificial turf and its negative effects.
Read More »NCHR Comments on USPSTF’s on Pancreatic Cancer Screening
March 4, 2019. We support the USPSTF’s draft recommendation against screening for pancreatic cancer in asymptomatic adults because screening asymptomatic adults does not improve patient outcomes and poses its own risks.
Read More »NCHR Testimony to FDA on Selinexor for Relapsed Refractory Multiple Myeloma
February 26, 2019. Selinexor has serious risks, and we don’t know if it works. Tell FDA to wait until the randomized trial is analyzed to make a decision.
Read More »